herpes simplex Articles
-
Duration of protection from live attenuated vs. sub unit HSV-2 vaccines in the guinea pig model of genital herpes: Reassessing efficacy using endpoints from clinical trials
Abstract Background Although herpes simplex viruses (HSV) are a major target for vaccine development no vaccine is currently licensed. Methods A live attenuated HSV virus vaccine, VC2 was compared to a subunit HSV vaccine, glycoprotein D (gD2) administered with the adjuvant, MPL/Alum using the guinea pig model of genital herpes. Three doses of intramuscular (IM) vaccine were provided followed by ...
-
RVx201 Herpes Vaccine
RVx201 Herpes Vaccine Description 2022 RVx201 is a first-in-human herpes simplex virus type 2 (HSV-2) live-attenuated therapeutic vaccine modified to be interferon sensitive that destroys the ability of the virus to inhibit immune responses. Produced by Rational Vaccines, Inc., the technology is based on the pioneering research of the late Dr. William Halford, who dedicated over 25 years to ...
-
Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1 (F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis
Abstract Herpes simplex virus type-1 (HSV-1) can cause severe ocular infection and blindness. We have previously shown that the HSV-1 VC2 vaccine strain is protective in mice and guinea pigs against genital herpes infection following vaginal challenge with HSV-1 or HSV-2. In this study, we evaluated the efficacy of VC2 intramuscular vaccination in mice against herpetic keratitis following ocular ...
-
Rational Vaccines Announces a Clinical Trial to Determine Baseline Characteristics of Patients Diagnosed With Recurrent Symptomatic Herpes Simplex Type 2 (HSV-2) Virus
Study to be conducted at two leading research institutions in the U.K. Results will inform protocol design of Phase 1/2 clinical trial of Company's lead HSV-2 therapeutic vaccine candidate WOBURN, Mass. and OXFORD, England, Aug. 15, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced the ...
-
The Major Breakthrough That Completely Stopped This Woman`s Painful Genital Herpes Outbreaks
In the span of seven days, Mel Smith left her verbally abusive boyfriend, moved out of their house with her 13-year-old son, and found out that she had contracted genital herpes. “I didn’t know what it was. I didn’t know what to do,” she says, remembering the time five years ago when her vagina itched so badly she couldn’t wear underwear. Her diagnosis? Herpes ...
-
Development of Gene Therapy Viral Vectors for Rare Diseases
In many cases, gene therapy requires a vector to deliver the gene therapy drug to the target cell. Viral vectors have been one of the most widely studied vectors due to their outstanding transduction efficiency and other significant advantages. Viral vector-based gene therapy has now achieved good clinical results. More than a dozen viral gene therapy products have been approved for the treatment ...
By Protheragen
-
Vaccine-induced antibodies target sequestered viral antigens to prevent ocular HSV-1 pathogenesis, preserve vision, and preempt productive neuronal infection
The cornea is essential for vision yet highly sensitive to immune-mediated damage following infection. Generating vaccines that provide sterile immunity against ocular surface pathogens without evoking vision loss is therefore clinically challenging. Here, we tested a prophylactic live-attenuated vaccine against herpes simplex virus type 1 (HSV-1), a widespread human pathogen that can cause ...
-
Constructing Oncolytic Viruses: A Revolutionary Approach in Cancer Therapeutics
The contemporary sphere of oncological therapeutics has witnessed a phenomenal shift in methodology, pivoting from conventional treatment modalities to exploring and utilizing the power of biological entities, notably viruses. Oncolytic virotherapy stands as an avant-garde dissertation in this evolution. It is predicated on the judicious fabrication of Oncolytic Viruses (OVs), biological entities ...
-
Rational`s Experimental Herpes Vaccine Shows Preclinical Promise
Rational Vaccines said findings from a pilot study showed that RVX201 led to a reduction in recurrent genital lesions when compared to gD2-alum/MPL vaccine in animal studies. Rational's Experimental Herpes Vaccine Shows Preclinical Promise Rational Vaccines said findings from a pilot study showed that RVX201 led to a reduction in recurrent genital lesions when compared to gD2-alum/MPL vaccine ...
-
A Rationally Designed Therapeutic Vaccine for Herpes
Founder and CEO, Agustin Fernand of Rational Vaccines that is developing a vaccine for herpes. There is a pandemic raging across the world – and it has nothing to do with a coronavirus. Approximately 500 million people worldwide suffer from genital herpes. Several billion more have an oral herpes infection. Herpes is a life-altering disease that can lead to chronic pain, blindness, and ...
-
Gene Therapy for Cystic Fibrosis
What is cystic fibrosis? Cystic fibrosis (CF) is a rare genetic disorder that affects the lungs, digestive system, and other organs. It is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes a protein that regulates chloride ions transport across cell membranes. These mutations cause the CFTR protein to be either absent or not function ...
By Protheragen
-
Sexually Transmitted Infections and Disease: The Silent Pandemic
Twenty-five years ago, the Institute of Medicine (IOM) published a report on confronting sexually transmitted diseases (STDs) as the “hidden epidemic of tremendous health and economic consequence in the United States, and that the scope, impact, and consequences of STDs are under recognized by the public and in healthcare.”1 Today, the United States is in the midst of a major ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you